17 results about "HER Inhibitors" patented technology

The invention relates to the technical field of biological medicines, in particular to application of four micro RNAs (Ribonucleic Acid) of miR-92a, miR-25, miR-30d and miR-30c and inhibitors targeting the four micro RNAs to preparation of medicines for resisting metastasis of multiple cancer species such as breast cancer, colorectal cancer and melanoma. When the nucleic acid inhibitor anti-agomirs targeting at least one of a set consisting of miR-92a, miR-25, miR-30d and miR-30c is used for treating metastasis of multiple cancer species, the anti-metastasis effect is remarkable, the universality is high, and the nucleic acid inhibitor anti-agomirs can show a strong inhibition effect in three different tumor metastasis models of breast cancer, colorectal cancer and melanoma; especially, when the four inhibitors are combined for use, the synergistic effect is prominent, the colorectal cancer liver metastasis load can be reduced by 90% or above, the breast cancer metastasis rate is reduced by 80% or above, the melanoma metastasis inhibition rate is 65% or above, and the composition is suitable for treatment of multi-cancer metastasis.

According to the invention, a novel immune checkpoint molecule SIDT1 is found. The SIDT1 is a powerful T cell inhibition factor mainly expressed on CD8 < + > T cells. A series of SIDT1 inhibitors are identified in the invention. The SIDT1 inhibitor can enhance the anti-tumor CD8T cell reaction and limit tumor progression, so that a new thought is provided for treatment and prevention of related tumor patients with PD-1 treatment resistance.

This invention discloses the application of SDC1 in the diagnosis and treatment of breast cancer. Through bioinformatics analysis, cell function experiments, multi-omics analysis, and animal model validation, this invention reveals for the first time the high expression of SDC1 in breast cancer and its correlation with poor patient prognosis. It elucidates the molecular mechanism by which SDC1 promotes the malignant progression of breast cancer by regulating ECM remodeling, EMT, angiogenesis, and ferroptosis resistance, and verifies the therapeutic potential of MZ1 in inhibiting breast cancer growth and metastasis by downregulating SDC1 expression. This invention provides the application of reagents for detecting SDC1 expression levels in the preparation of diagnostic or prognostic kits for breast cancer, as well as the application of SDC1 inhibitors in the preparation of drugs for treating breast cancer. This invention provides new technical solutions for the diagnosis, prognostic assessment, and treatment of breast cancer.

The invention belongs to the technical field of biological medicine, and relates to application of H1FX as a therapeutic target and application of three compounds as H1FX inhibitors in preparation of drugs for preventing and / or treating prostatic cancer. Experimental results show that up-regulation of H1FX expression level can promote proliferation of prostate cancer cells, and knock-down of H1FX can inhibit proliferation of prostate cancer cells. H1FX expression up-regulation can significantly promote generation and development of prostate cancer cell line nude mouse subcutaneous tumor formation. Researches show that the three compounds are specifically combined with H1FX, and proliferation of prostate cancer cells and growth of subcutaneous tumors of nude mice with prostate cancer cell strains are inhibited. Therefore, the invention provides a new target for the design of new anti-prostatic cancer drugs, and provides a new thought for the development and preparation of prostatic cancer prevention and / or treatment drugs.

This invention relates to the pharmaceutical applications of MRPS7 as a diagnostic biomarker for non-small cell lung cancer (NSCLC) and its inhibitors, belonging to the field of biomedical technology. For the first time, this invention utilizes immunohistochemical analysis of tumor tissues from NSCLC patients and paired adjacent normal tissues to confirm that MRPS7 protein is significantly overexpressed in NSCLC tissues (p<0.001), and this difference is statistically significant in both lung adenocarcinoma and lung squamous cell carcinoma subtypes. Furthermore, this invention demonstrates through in vitro functional experiments that knocking down MRPS7 gene expression using siRNA targeting MRPS7 significantly inhibits the proliferation, migration, and invasion abilities of NSCLC cells (A549, SK-MES-1) (p<0.001). Therefore, reagents for detecting MRPS7 expression levels can be used to prepare NSCLC diagnostic products, and MRPS7 inhibitors can be used to prepare drugs for treating NSCLC. This invention provides a novel molecular biomarker for the diagnosis of NSCLC and a new strategy for targeted therapy of NSCLC.

This invention discloses the application of β-1,4-galactosyltransferase 1 and its inhibitors in liver diseases, particularly acute liver injury and liver failure. The application of β-1,4-galactosyltransferase 1 and its inhibitors in acute liver injury and liver failure provides the correlation between β-1,4-galactosyltransferase 1 and acute liver injury and liver failure, confirming that inhibiting the activity of β-1,4-galactosyltransferase 1 can alleviate acute liver injury and liver failure. β-1,4-galactosyltransferase 1 can serve as a drug target for screening acute and chronic hepatitis, liver injury, fatty liver, liver fibrosis, and acute and chronic liver failure. This invention also confirms the alleviating effect of β-1,4-galactosyltransferase 1 inhibitors on acute liver failure. β-1,4-galactosyltransferase 1 inhibitors improve acute liver failure by reducing the enzyme activity or protein expression of β-1,4-galactosyltransferase 1.

This invention belongs to the field of biomedical technology and discloses the application of CCR2 inhibitors in the preparation of drugs for treating hemophagocytic lymphohistiocytosis (HLH). By establishing a mouse model of HLH, this invention reveals for the first time that CCR2 can serve as an effective drug target for treating HLH. Experiments showed that treatment with the CCR2-specific antagonist RS102895 significantly reduced splenomegaly, improved peripheral blood cell reduction, alleviated liver damage, corrected metabolic disorders in model mice, and effectively inhibited serum cytokine storm and abnormal activation of splenic macrophages. Based on these findings, CCR2 can serve as a novel target for HLH treatment, and its inhibitors can be used to prepare highly effective and low-toxicity drugs for treating HLH.

The invention relates to the technical field of medicines, in particular to miRNA-181a-5p and application of an inhibitor of miRNA-181a-5p in a medicine for treating lower limb arteriosclerosis obliterans. The research on disease pathogenesis finds that miRNA-181a-5p is particularly important in the occurrence and development process of lower limb arteriosclerosis obliterans, and the miRNA-181a-5p inhibitor is adopted to treat vascular endothelial cells, so that the functions of the vascular endothelial cells can be improved, including improvement of migration and tubular formation of the vascular endothelial cells; the proliferation function is improved; the ROS generation is reduced.

This invention relates to the application of PLEKHH1 and its inhibitors in the preparation of drugs or kits that induce ferroptosis, belonging to the field of tumor treatment technology. This invention discovers that knocking down the PLEKHH1 gene in liver cancer cells can induce ferroptosis. Therefore, this invention uses the PLEKHH1 gene as a novel target for cancer cells to resist ferroptosis. By knocking down this gene, it eliminates ferroptosis escape from cancer cells, induces ferroptosis, and thus exerts a therapeutic effect on tumors.

The present application relates to acetaldehyde dehydrogenase 1 family member A3, and particularly to the application of acetaldehyde dehydrogenase 1 family member A3 and its inhibitor in the preparation of a drug for chronic heart failure. The present application discloses the application of acetaldehyde dehydrogenase 1 family member A3 as a drug target in the preparation of a drug for chronic heart failure. The present application first discloses the correlation between acetaldehyde dehydrogenase 1 family member A3 and chronic heart failure, and confirms that the vascular endothelial injury can be improved by specific knockdown or interference of ALDH1A3 to treat chronic heart failure, which indicates that ALDH1A3 can become a new target for treating chronic heart failure or cardiovascular diseases. Therefore, acetaldehyde dehydrogenase 1 family member A3 can be used as a target for screening a drug for preventing, relieving and / or treating chronic heart failure.

This invention discloses a long non-coding RNA that regulates protease degradation, its inhibitor, and its applications, belonging to the field of cell biology. The nucleotide sequence of the long non-coding RNA is shown in SEQ ID NO.1, and the reagent for inhibiting the long non-coding RNA includes knocking out the shRNA expressed by the long non-coding RNA. This invention enhances the ubiquitination modification of HK1 by knocking down lncHBHK1 (NONCODE database name: RP11-675F6.3), thereby accelerating the degradation of HK1 protein and inhibiting the proliferation of liver cancer cells. Combined with animal experiments, it is further confirmed that knocking down the expression level of this lncRNA in vivo can inhibit the growth of liver cancer tumors, indicating that this lncRNA has the potential to serve as a novel therapeutic target for liver cancer and provides a new strategy for developing drugs to treat liver cancer.

This invention provides the application of GCKR and its inhibitors in the preparation of drugs for treating pancreatic cancer, belonging to the field of biomedical technology. The application of GCKR and its inhibitors in the preparation of drugs for treating pancreatic cancer reveals for the first time that GCKR is a key metabolic switch driving liver metastasis in pancreatic cancer, and that high expression of the GCKR gene can promote the growth and liver metastasis of pancreatic cancer in mice. The proliferation, invasion, and migration abilities of pancreatic cancer cells in the GCKR low-expression group were significantly lower than those in the normal control group. Using a pancreatic cancer orthotopic xenograft model constructed in highly immunodeficient mice, the invention demonstrated in vivo that knocking out GCKR can inhibit the growth of pancreatic cancer, indicating that GCKR inhibitors block the progression of pancreatic cancer by downregulating GCKR; conversely, overexpression plasmids that promote GCKR expression can upregulate GCKR expression and promote pancreatic cancer progression. This provides a new application of GCKR and offers new ideas for the treatment of pancreatic cancer.

This invention relates to the field of biomedical technology, specifically to a micromolecule RNA-19b-3p and its application in the treatment of pancreatic ductal adenocarcinoma. The micromolecule RNA-19b-3p has the nucleotide sequence shown in SEQ ID NO:1. This invention discloses its use in the preparation of a medicament for treating pancreatic ductal adenocarcinoma, achieved by inhibiting the expression and / or activity of the micromolecule RNA-19b-3p. The medicament comprises a substance capable of reducing the expression or activity of the micromolecule RNA-19b-3p. This substance is its inhibitor, suppressor, antagonist, or antisense oligonucleotide. The medicament is used to inhibit the proliferation, migration, and / or invasion of pancreatic ductal adenocarcinoma cells. This invention provides a novel biomarker and therapeutic intervention target for pancreatic ductal adenocarcinoma, clarifies the feasibility of targeted therapy, and possesses clear translational potential.

This invention relates to the field of biomedical technology, specifically to a micromolecule RNA-191-5p and its application in the treatment of pancreatic ductal adenocarcinoma. The micromolecule RNA-191-5p has the nucleotide sequence shown in SEQ ID NO:1. This invention discloses its use in the preparation of a medicament for treating pancreatic ductal adenocarcinoma, achieved by inhibiting the expression and / or activity of the micromolecule RNA-191-5p. The medicament comprises a substance capable of reducing the expression or activity of the micromolecule RNA-191-5p. This substance is its inhibitor, suppressor, antagonist, or antisense oligonucleotide. The medicament is used to inhibit the proliferation, migration, and / or invasion of pancreatic ductal adenocarcinoma cells. This invention provides a novel biomarker and therapeutic intervention target for pancreatic ductal adenocarcinoma, clarifies the feasibility of targeted therapy, and possesses clear translational potential.

This invention discloses the application of a tumor drug marker, the protein kinase HUNK, in the preparation of drugs for treating tumors and metastatic diseases. These drugs include components for inhibiting HUNK expression and nanomedicines. This invention inhibits cellular endocytosis mediated by caveolin, a major pathway for nanomedicines such as albumin-bound paclitaxel to enter cells. The sirna of this protein and its inhibitors can serve as nanomedicine therapies for cancers with high HUNK gene expression. In experimental applications, tumor cells with high HUNK gene expression are insensitive to albumin-bound paclitaxel, while cells treated with HUNK knockout or its inhibitor are more sensitive. Experiments showed that knockout or inhibition of HUNK promotes albumin endocytosis and its entry into lysosomes for degradation.

The present invention relates to a drug, a combination agent, a pharmaceutical composition or a preparation for treating or preventing ALK fusion gene-positive cancer, which comprises an ALK inhibitor and a TNKS inhibitor in combination or comprises a pan-HER inhibitor in combination therewith, and a method for treating or preventing the cancer, as well as an agent for inhibiting the growth of ALK fusion gene-positive cancer which is resistant to the ALK inhibitor on a temporary basis, and the like.

The invention belongs to the technical field of biology, and particularly relates to application of an OGG1 inhibitor to treatment of osteogenic differentiation disorder bone defects. Mainly provides application of an OGG1 inhibitor in preparation of a medicine for treating osteogenic differentiation disorder bone defects. The OGG1 specific small-molecule inhibitor TH5487 is introduced as a candidate drug for treating osteogenic differentiation disorder bone defects, compared with an existing osteogenesis promoting drug, the OGG1 specific small-molecule inhibitor TH5487 has the advantages of being definite in target spot and clear in action mechanism, negative regulation and control of OGG1 on osteogenic differentiation can be relieved by inhibiting the activity of OGG1, and therefore precise intervention on the bone formation process is achieved, and the effect of treating osteogenic differentiation disorder bone defects is achieved. The invention also provides a theoretical basis and a technical scheme for the application of the OGG1 gene / protein and the inhibitor thereof in medicines for treating bone formation related diseases, and the OGG1 gene / protein has good clinical transformation potential and application prospect.